Evidence map›Paper›PMID 39464295›Full record

ArticlemicroPublication biology2024

Polo-like kinase inhibition leads to neuroprotection of neurons bearing alpha-synuclein Lewy body-like inclusions

Elizabeth P Rose, Jovin S Banga, Vivek K Unni

Abstract read
In one paragraph

Article in microPublication biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elizabeth P RoseJungers Center for Neurosciences Research, Oregon Health & Science University, Portland, Oregon, United States.
Jovin S BangaJungers Center for Neurosciences Research, Oregon Health & Science University, Portland, Oregon, United States.
Vivek K UnniJungers Center for Neurosciences Research, Oregon Health & Science University, Portland, Oregon, United States.

Funding

Research Education ComponentP30AG066518 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KEVIN M DUFF, Lisa C Silbert · 2020 to 2026
$28.6M
Neuroscience of Aging, Neurodegeneration and Alzheimer’s DiseaseT32AG055378 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI JACOB RABER, HENRYK F URBANSKI · 2018 to 2026
$4.3M
Mechanisms of Neurodegeneration in Lewy Body DisordersR01NS102227 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI UNNI, VIVEK · 2017 to 2021
$1.9M
NIA NIH HHS P30 AG066518NIA NIH HHS T32 AG055378NINDS NIH HHS R01 NS102227
6 · The paper itself

Abstract

α-synuclein (αSyn) and S129 phosphorylated αSyn (pSyn) define synucleinopathies like Parkinson's disease (PD). Targeting S129 αSyn kinases, like the Polo-like kinase (PLK) family, could provide a therapeutic strategy to limit degeneration of cells bearing aggregated αSyn inclusions. Using longitudinal

Identifiers

PMID39464295
PMCPMC11507930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.